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Purpose: To determine the inherent risks of handling results below the lowest
detectable value in the analysis of multiple cytokines in the aqueous humor of patients
with retinal diseases by comparing possible statistical strategies to lower the risk of
mis interpretation or over interpretation of results. Furthermore, in analyzing multiple
cytokines simultaneously, the challenge of multiple comparison arises.
Methods: The analyses were based on parallel testing of 43 cytokines in 58 aqueous
humor samples frompatientswithmacular hole or epiretinalmembrane. Substitution of
values below thedetection limitwith 0.1×, 0.5×, or 1.0×of the lowest level of quantita-
tionwas comparedwith handling asmissing value. The impact of correction formultiple
comparisons was assessed using the Holm correction.
Results:When comparingmacular hole with epiretinal membrane, not substituting the
missing data revealed a difference (P < 0.05) for five compared with wight cytokines
after their substitution, indicating an increased risk for under-estimating group differ-
ences (type II error). Correcting for multiple comparisons revealed a relevant risk of over
estimating group differences (type I error).
Conclusions: Physiologic cytokine concentrations in ocular fluids typically range at or
below the lowest level of quantitation. Handling of results below this cutoff as missing
leads to increased type II errors. Not correcting for multiple comparisons increases the
risk of a type I error. Taken together, both harbor a systematic inherent risk of misinter-
pretation of the results.
Translational Relevance: Ignoring the inherent risks of datamisinterpretation in analy-
ses of ocular fluid samples may result in mis leading conclusions regarding their biolog-
ical relevance.
Introduction
An analysis of intraocular fluids means assessing
concentrations of targets, be it proteins, antibodies,
cytokines, or drugs, at or below the lower end of
sensitivity of commercially available test systems. The
concentration of antibodies and albumin in intraocu-
lar fluids, for example, ranges between 200- and 1000-
fold lower than in serum.1,2 This condition interferes
with the test reliability, because the reading out of
results based on standard curves in this lower range
is not very reliable or reproducible. Manufacturers of
analytical devices do not advocate using data below
the lower threshold of a test system, therefore these
results require special consideration. Some authors
propose to discard these data or suggest the out of
range (OOR) data be set to zero.3–5 Other investigators
have reported substitution of concentrations below the
detection limit with 0.5 times of the lowest point of the
calibration curve.6
While evaluating our own test results generated
by a multiplex beads system in cytokine/chemokine
research of intraocular fluids,7–12 we experienced
several challenges with data handling. Because many
researchers in this field likely have similar experiences,
our goal was to systematically assess different statistical
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methods and outcomes to determine the best approach
to handle this type of data.
A detection limit of 1 pg is recommended for the
majority of detectable cytokines by the manufactur-
ers of sensitive immunobeads systems (e.g., Bio-Rad
multiplex immunoassays; Bio-Rad, Hercules, CA).
This raises the question of how to statistically handle
OOR values in ocular and other samples, which may
apply to a considerable proportion of samples quanti-
fied in cytokine research (In our data we rarely had the
case of single data points laying above the standard
curve range. If a single sample shows unexplained
high values, a repeat parallel double testing should be
considered. The solution to systematically high target
values in a series would be a higher dilution of samples
prior to submission to the test.).
Multiplex assays allow for the quantification of
multiple targets in parallel in a small volume andwithin
a single test run. The inherent problem with multiple
comparisons is an increased risk for a type I error,
which results in an overinterpretation of the results.
Discussions and possible solutions to this problem
have already been discussed since the early 1960s.13
Although available, the statistical tools to control for
multiple comparisons have as yet not routinely been
established. Therefore, we addressed the impact of data
handling and of correction for multiple comparisons
based on a set of cytokine data derived from aqueous
samples from patients with two similar and specific
ocular diagnoses (macular hole [MH] and epiretinal




This prospective clinical study included aqueous
humor (AH) samples from eyes with symptomatic
idiopathic ERM (n = 29) or MH (n = 29) undergoing
vitrectomy.
Clinical data pertaining to the systemic and ophthal-
mologic diagnoses, the treatment strategy, and the
duration of the ocular symptoms were documented.
Patients with systemic comorbidities, that is, with
diabetes mellitus, a history of intraocular surgery
(other than uneventful phacoemulsification for senile
cataract, performed minimally 6 months before vitrec-
tomy), known rheumatic and autoimmune diseases,
systemic treatments involving corticosteroids or
immunomodulatory drugs, ocular trauma, vitreal
hemorrhaging, uveitis, glaucoma, or any concomitant
retinal pathology, were excluded. Also excluded were
patients who had undergone intraocular surgery or
treatment within 6 months before sample collection.
Patients with prior surgery, such as cataract surgery,
were only included in cases of uneventful surgery.
No patient had a posterior capsular tear or violation.
The results of the corresponding vitreous analyses
have been published.7 Surgery was performed at the
Berner Augenklinik am Lindenhofspital in Bern after
informed, written consent of the individuals had been
obtained for vitrectomy and ocular fluid sampling.
This study is fully compliant with the tenets of the
Declaration of Helsinki and was approved by the
Institutional Ethics Board of the University of Bern,
Switzerland (registration number: 152/08).
UndilutedAH samples (approximately 100 μL)were
collected at the beginning of surgery and immedi-
ately stored at –80°C until analysis. All samples were
analyzed in parallel using a multiplex beads system
(Bio-Plex 100 array reader with Bio-Plex Manager
software version 6.1; Bio-Rad; human chemokine
assay with 40 cytokines: P171-AK99MR2 and TGF-
β 3-plex assay: 171W4001M). With this highly sensi-
tive technique, multiple analytes can be detected in
parallel using a single small volume sample. For the
purpose of this study, we quantified the concentra-
tions of 43 cytokines in each aqueous sample (Tables 1
and 2). All analytic procedures were performed follow-
ing the manufacturer’s instructions. In short, magnetic
microspheres, tagged with a fluorescent label, were
coupled to specific capture antibodies and mixed
with samples containing unknown cytokine quanti-
ties before introducing biotinylated detection antibod-
ies and streptavidin R-phycoerythrin. The mixture was
then analyzed by flow cytometry. The instrument’s
two lasers identify the microsphere type and quantify
the amount of bound antigen. On each test plate we
ran a duplicate concentration standard in parallel for
each cytokine. The measurements were performed in
a blinded manner by a laboratory technician who was
experienced in the execution of this technique.
Statistical Workup of Data
The concentration of cytokines below the standard
curve of fit were registered as missing values and thus
excluded by the automated software provided with the
reader. Because the handling of these data as missing
values constitutes a loss of information, we compared
different options for handling of OOR values below the
lower limit of quantification (LLOQ) provided by the
manufacturer by either (a) accounting them as missing,
(b) by substituting the OOR data with the lower limit
of detection (LOD) specific in our sample, or (c) substi-
tuting them with different fractions of the LLOQ, that
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Table 1. Descriptive Results for Cytokine Concentrations in the AH of 29 Eyes With MHWithout and After Substi-
tution of OOR Data With Different Proportions of the LLOQ
With With With With With
Substitution Substitution Substitution Substitution Substitution
of OOR by of OOR by by 0.1 of by 0.5 of by 1.0 of
Missing Values the LOD the LLOQ the LLOQ the LLOQ
Kruskal
Cytokine OOR -Wallis
(pg/mL) n data Mean SD Mean SD Mean SD Mean SD Mean SD H Test
CCL21 28 1 777.9 347.2 761.8 351.8 751.2 370.1 751.5 369.5 751.9 368.7 0.9992
CXCL13 10 19 0.7 0.9 0.3 0.6 0.3 0.6 0.5 0.5 0.7 0.5 3.77E-11
CCL27 7 22 3.4 5.2 0.9 2.8 0.9 2.8 1.3 2.7 1.7 2.6 4.77E-13
CXCL5 27 2 177.3 139.4 165.3 141.6 165.1 141.8 165.3 141.6 165.5 141.3 0.9888
CCL11 28 1 5.4 2.3 5.3 2.4 5.2 2.5 5.3 2.4 5.3 2.4 0.9993
CCL24 29 0 27.2 14.4 27.2 14.4 27.2 14.4 27.2 14.4 27.2 14.4 1
CCL26 24 5 4.3 2.7 3.6 2.9 3.6 3.0 3.6 2.9 3.7 2.8 0.766
CX3CL1 29 0 43.2 17.9 43.2 17.9 43.2 17.9 43.2 17.9 43.2 17.9 1
CXCL6 9 20 1.3 1.2 0.6 0.8 0.5 0.9 0.7 0.8 1.0 0.7 6.49E-08
GM-CSF 29 0 145.9 97.7 145.9 97.7 145.9 97.7 145.9 97.7 145.9 97.7 1
CXCL1 27 2 43.9 22.0 41.1 23.5 40.9 24.0 41.0 23.8 41.1 23.7 0.989
CXCL2 10 19 8.1 2.3 6.2 1.9 3.1 3.9 4.3 3.1 5.8 2.1 4.15E-06
CCL1 24 5 12.9 8.6 11.6 8.3 10.7 9.2 10.8 9.1 11.0 8.9 0.76
IFN-γ 3 26 5.2 2.7 2.4 1.2 0.7 1.7 1.6 1.4 2.6 1.1 1.01E-15
IL-1β 29 0 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 1
IL-2 25 4 0.6 0.7 0.5 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.5298
IL-4 3 26 2.6 1.9 1.3 0.7 0.4 0.9 0.8 0.8 1.3 0.7 2.20E-16
IL-6 29 0 26.1 92.6 26.1 92.6 26.1 92.6 26.1 92.6 26.1 92.6 1
IL-8/CXCL8 29 0 5.6 6.4 5.6 6.4 5.6 6.4 5.6 6.4 5.6 6.4 1
IL-10 24 5 3.8 2.9 3.4 2.9 3.2 3.0 3.3 2.9 3.4 2.8 0.77
IL-16 28 1 14.8 10.7 14.3 10.8 14.8 10.7 14.3 10.8 14.8 10.7 1.00
CXCL10 29 0 43.6 34.0 43.6 34.0 43.6 34.0 43.6 34.0 43.6 34.0 1
CXCL11 25 4 1.1 0.8 1.0 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.88
CCL2 29 0 452.6 236.9 452.6 236.9 452.6 236.9 452.6 236.9 452.6 236.9 1
CCL8 29 0 2.8 1.8 2.8 1.8 2.8 1.8 2.8 1.8 2.8 1.8 1
CCL7 1 28 5.8 4.6 0.2 0.4 1.0 1.1 0.9 2.0 0.7 2.20E-16
CCL13 29 0 1.3 0.6 1.3 0.6 1.3 0.6 1.3 0.6 1.3 0.6 1
CCL22 23 6 9.7 4.7 8.4 4.9 7.7 5.7 7.7 5.6 7.8 5.5 0.6278
MIF 29 0 38758.7 19067.5 38758.7 19067.5 38758.7 19067.5 38758.7 19067.5 38758.7 19067.5 1
MIG/
CXCL9 29 0 14.8 18.2 14.8 18.2 14.8 18.2 14.8 18.2 14.8 18.2 1
CCL3 27 2 1.0 0.4 0.9 0.5 0.9 0.5 0.9 0.5 0.9 0.5 0.99
CCL15 29 0 516.3 532.7 516.3 532.7 516.3 532.7 516.3 532.7 516.3 532.7 1
CCL20 29 0 3.4 3.1 3.4 3.1 3.4 3.1 3.4 3.1 3.4 3.1 1
CCL19 13 16 7.4 4.9 3.4 4.9 3.5 4.8 4.2 4.4 5.0 3.9 0.001232
CCL23 21 8 16.3 9.3 12.0 10.6 11.8 10.7 11.9 10.6 12.1 10.5 0.3512
CXCL16 29 0 474.2 182.8 474.2 182.8 474.2 182.8 474.2 182.8 474.2 182.8 1
CXCL12 27 2 109.9 68.0 103.6 69.7 102.4 71.3 102.6 71.0 102.9 70.6 0.99
CCL17 2 27 3.9 2.2 0.3 1.1 0.4 1.0 1.1 0.9 1.9 0.7 2.20E-16
CCL25 29 0 106.0 63.1 106.0 63.1 106.0 63.1 106.0 63.1 106.0 63.1 1
TNF-α 29 0 5.6 4.5 5.6 4.5 5.6 4.5 5.6 4.5 5.6 4.5 1
TGF-β1 26 3 225.9 137.8 203.5 146.4 202.6 147.8 202.6 147.7 202.7 147.6 0.95
TGF-β2 29 0 3337.8 1435.4 3337.8 1435.4 3337.8 1435.4 3337.8 1435.4 3337.8 1435.4 1
TGF-β3 5 24 16.9 18.7 3.4 9.4 3.1 9.5 4.1 9.2 5.2 8.9 6.93E-12
LLOQ: Lower limit of quantitation; LOD: lower of detection; SD: Standard deviation. Significant p-values are marked in bold.
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Table 2. Descriptive Results for Cytokine Concentrations in the AH of EyesWith an ERMWithout and After Substi-
tution of OOR Data With Different Proportions of the LLOQ
With With MHWith MHWith MHWith
Substitution Substitution Substitution Substitution Substitution
of OOR by of OOR by by 0.1 of by 0.5 of by 1.0 of
Missing Values the LOD the LLOQ the LLOQ the LLOQ
Kruskal
Cytokine OOR -Wallis
Cytokine n data Mean SD Mean SD Mean SD Mean SD Mean SD H Test
CCL21 29 0 1140.0 662.0 1140.0 662.0 1140.0 662.0 1140.0 662.0 1140.0 662.0 1.0
CXCL13 17 12 0.4 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.5 0.3 9.98E-05
CCL27 5 24 1.2 1.6 0.2 0.8 0.3 0.7 0.7 0.7 1.2 0.6 7.07E-16
CXCL5 29 0 2444.4 3566.4 2444.4 3566.4 2444.4 3566.4 2444.4 3566.4 2444.4 3566.4 1.0
CCL11 29 0 8.8 3.1 8.8 3.1 8.8 3.1 8.8 3.1 8.8 3.1 1.0
CCL24 29 0 30.9 14.2 30.9 14.2 30.9 14.2 30.9 14.2 30.9 14.2 1.0
CCL26 20 9 3.3 2.0 2.4 2.1 2.3 2.2 2.4 2.1 2.5 2.0 0.2569
CX3CL1 29 0 39.9 19.1 39.9 19.1 39.9 19.1 39.9 19.1 39.9 19.1 1.0
CXCL6 10 19 1.7 1.1 0.8 0.9 0.6 1.0 0.8 0.9 1.1 0.7 6.43E-06
GM-CSF 29 0 90.4 35.3 90.4 35.3 90.4 35.3 90.4 35.3 90.4 35.3 1.0
CXCL1 27 2 47.4 18.2 44.4 20.8 44.2 21.3 44.2 21.1 44.3 20.9 0.99
CXCL2 5 24 11.8 1.4 6.3 2.6 2.4 4.4 3.9 3.7 5.8 2.8 6.93E-12
CCL1 3 26 12.1 5.2 6.0 2.5 1.4 4.0 2.1 3.7 2.9 3.5 1.01E-15
IFN-γ 6 23 5.2 3.5 2.7 2.0 1.3 2.5 2.0 2.2 2.9 1.9 3.31E-12
IL-1β 28 1 0.9 0.7 0.9 0.7 0.9 0.7 0.9 0.7 0.9 0.7 1.00
IL-2 24 5 0.9 0.7 0.7 0.7 0.7 0.7 0.8 0.7 0.8 0.6 0.54
IL-4 20 9 31.1 29.1 21.8 27.8 21.5 28.0 21.6 27.9 21.8 27.8 0.23
IL-6 29 0 9.0 10.8 9.0 10.8 9.0 10.8 9.0 10.8 9.0 10.8 1.0
IL-8 /CXCL8 29 0 9.1 7.1 9.1 7.1 9.1 7.1 9.1 7.1 9.1 7.1 1.0
IL-10 29 0 5.5 1.8 5.5 1.8 5.5 1.8 5.5 1.8 5.5 1.8 1.0
IL-16 28 1 16.9 9.0 16.4 9.3 16.9 9.0 16.3 9.3 16.9 9.0 1.00
CXCL10 29 0 42.9 24.7 42.9 24.7 42.9 24.7 42.9 24.7 42.9 24.7 1.0
CXCL11 29 0 1.0 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.0
CCL2 29 0 452.3 262.6 452.3 262.6 452.3 262.6 452.3 262.6 452.3 262.6 1.0
CCL8 29 0 2.9 1.6 2.9 1.6 2.9 1.6 2.9 1.6 2.9 1.6 1.0
CCL7 4 25 8.9 2.9 5.2 1.8 1.4 3.2 2.0 3.0 2.9 2.6 2.74E-14
CCL13 29 0 2.1 1.3 2.1 1.3 2.1 1.3 2.1 1.3 2.1 1.3 1.0
CCL22 24 5 13.2 6.6 11.5 7.1 10.9 7.8 11.0 7.7 11.1 7.6 0.77
MIF 29 0 14260.8 25156.5 14260.8 25156.5 14260.8 25156.5 14260.8 25156.5 14260.8 25156.5 1.0
MIG/
CXCL9 28 1 12.7 7.8 12.4 7.9 12.3 8.0 12.3 8.0 12.3 8.0 1.00
CCL3 26 3 1.2 0.5 1.1 0.6 1.1 0.6 1.1 0.6 1.1 0.6 0.95
CCL15 29 0 497.4 326.7 497.4 326.7 497.4 326.7 497.4 326.7 497.4 326.7 1.0
CCL20 29 0 3.8 3.3 3.8 3.3 3.8 3.3 3.8 3.3 3.8 3.3 1.0
CCL19 26 3 9.3 4.6 8.3 5.1 8.3 5.1 8.5 4.9 8.6 4.7 0.95
CCL23 27 2 14.7 7.5 13.7 8.1 13.7 8.2 13.7 8.1 13.7 8.1 0.99
CXCL16 29 0 588.4 235.6 588.4 235.6 588.4 235.6 588.4 235.6 588.4 235.6 1.0
CXCL12 29 0 107.5 59.5 107.5 59.5 107.5 59.5 107.5 59.5 107.5 59.5 1.0
CCL17 1 28 0.1 0.1 0.0 0.2 0.0 0.8 0.1 1.6 0.3 2.20E-16
CCL25 29 0 56.6 55.1 56.6 55.1 56.6 55.1 56.6 55.1 56.6 55.1 1.0
TNF-α 29 0 6.2 2.8 6.2 2.8 6.2 2.8 6.2 2.8 6.2 2.8 1.0
TGF-β1 21 8 157.7 174.6 116.8 162.2 114.3 164.1 114.4 163.9 114.7 163.7 0.34
TGF-β2 29 0 2910.6 1033.6 2910.6 1033.6 2910.6 1033.6 2910.6 1033.6 2910.6 1033.6 1.0
TGF-β3 19 10 14.1 23.5 9.4 20.0 9.3 20.0 9.7 19.8 10.2 19.7 0.10
LLOQ: Lower limit of quantitation; LOD: lower of detection; SD: Standard deviation. Significant p-values are marked in bold.
Downloaded from tvst.arvojournals.org on 03/11/2021
The Simultaneous Analyses of Multiple Cytokines TVST | June 2020 | Vol. 9 | No. 7 | Article 27 | 5
is, a factor of 0.1, 0.5, or 1.0 (fractions) of the LLOQ.
Numerical and statistical outcomes were compared in
relation to the handling of results in fractions (LOD; 0,
0.1, 0.5, or 1.0-fold the LLOQ).
Because most of the data were not normally
distributed, a series of nonparametric Kruskal-Wallis
H tests were applied to compare the different substi-
tutions of the data below the detection limit (OOR<
data). Mann–Whitney U tests were applied for each
cytokine to explore the difference between MH and
ERM. Statistical evaluation was performed using the R
statistical package psych (version 3.2.4; R: A language
and environment for statistical computing, R Founda-
tion for Statistical Computing, Vienna, Austria, 2016).
Because multiple comparisons increase the risk of
introducing a type I error (declaring a result statis-
tically significant when it is not), we adjusted the
significance level to prevent falsely claiming statisti-
cal significance.14 The classic approach to the multi-
ple comparison problem is to control the family-wise
error rate.15 To escape this problem, the critical P level
for significance, or alpha, is frequently arbitrarily set
more restrictively (i.e., P < 0.01). One relatively simple
approach is the application of Bonferroni’s correc-
tion.16 This correction is a rather conservative estimate
that in turn leads to a higher risk for type II errors
(not declaring a result as statistically significant, when
it is in fact significant).14 To control for type I errors,
but without driving up the risk of type II errors, the
Holm correction was established as a more qualified
approach17,18 and applied here for correction of the
statistical outcomes.
Holm’s correction is a sequentially rejective Bonfer-
roni test that progressively adapts the threshold for
rejecting the null hypothesis. As a first step, all P values
are sorted of smallest to largest, with k indicating the
number of hypotheses. In a second step, the lowest P
value is compared with α/k. If the P value is lower,
the null hypothesis is rejected and the significance of
a result is confirmed. The same procedure is applied
to the remaining k – 1 hypotheses where the thresh-
old of significance is set at α/(k – 1). This procedure is
repeated sequentially for eachP value, until the selected
P value is higher than the sequential threshold.
Results
Patients of bothMHandERMgroupswere compa-
rable regarding age at the time of inclusion (70.0 ± 8.7
and 67.4 ± 8.0 years, respectively; P = 0.17), as well
as sex (80% females in the ERM group compared with
55% females in the MH group; P = 0.052).
Handling of OOR Data
The AH samples in MH provided results below
the detection threshold for 25 out of the 43 cytokines
(OOR<: CCL21, CXCL13, CCL27, CXCL5, CCL11,
CCL26, CXCL6, CXCL1, CXCL2, CCL1, interferon
[IFN]-γ , IL-2, IL-4, IL-10, IL-16, CXCL11, CCL7,
CCL22, CCL3, CCL19, CCL23, CXCL12, CCL17,
transforming growth factor [TGF]-β1, and TGF-
β3; Table 1). For nine cytokines (20.9%), more than
two-thirds of the samples (CXCL13, CCL27, CXCL6,
CXCL2, IFN-γ , IL-4, CCL7, CCL17, and TGF-β3)
ranged below the lower LOD (Table 1).
In samples from eyes with ERM, 21 of 43
cytokines presented results below the detection thresh-
old (OOR<: CXCL13, CCL27, CCL26, CXCL6,
CXCL1, CXCL2, CCL1, IFN-γ , IL-1β, IL-2, IL-4,
IL-16, CCL7, CCL22, MIG/CXCL9, CCL3, CCL19,
CCL23, CCL17, TGF-β1 and TGF-β3; Table 2).
Again, in seven of these (16.3%) cytokines, more than
two-thirds of all samples tested (CCL27, CXCL6,
CXCL2, CCL1, IFN- γ , CCL7, and CCL17) ranged
below the lower LOD (Table 2).
Comparing MH and ERF samples with and
without the substitution of the OOR data revealed a
relevant difference in the mean values and standard
deviations for all cytokines in which more than two-
thirds of the results ranged below the detection limit
(Tables 1 and 2). It remains to be discussed, whether a
statistical comparison in this situation is meaningful at
all.
If the OOR data were handled as missing values,
a significant difference between MH and ERM was
found for 14 cytokines. When the OOR data were
substituted with any of the fractions of the LLOQ, a
significant difference between the two groups was also
observed for 14 cytokines. The substitution with the
LOD or with a factor of 0.1 to 1.0 of the LLOQ led
to similar results (Table 3).
Correcting for Multiple Comparisons
When the OOR data were not substituted, after
applying the Holm correction, the difference remained
significant for 5 of the 14 cytokines (Table 3). The
difference in the number of significances in the compar-
ison of ERM and MH (five vs 14) was significant (P =
0.019). After substitution of OOR data, and applying
the Holm correction, the difference remained signifi-
cant for 8 of the 14 cytokines (Table 3). However, the
difference in the number of significances in the compar-
ison of ERM and MH (eight vs. 14) did not remain
significant (P = 0.14). The different substitutions
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Table 3. Statistical Outcomes After Comparison of the Cytokine Concentrations Within the AH in MH and ERM
With Substitution of OOR Data With Half of the LLOQ
Comparison Between Comparison Between Comparison Between
MH and ERMWith MH and ERMWith MH and ERMWith
No Substitution Substitution of Substitution of OOR by
of OOR OOR by LOD o.5 the LLOQ
Mann-Whitney Holm’s Mann-Whitney Holm’s Mann-Whitney Holm’s
Cytokine U test correction U test correction U test correction
CL21 0.008444 0.005246 0.005247
CXCL13 0.6151 0.2729 0.8327
CCL27 0.9352 0.3572 0.9912
CXCL5 0.3889 0.2102 0.216
CCL11 4.99E-05 Sig. 2.95E-05 Sig. 2.95E-05 Sig.
CCL24 0.04914 0.04914 0.04914
CCL26 0.3395 0.09494 0.07539
CX3CL1 0.3234 0.3234 0.3234
CXCL6 0.4065 0.3999 0.2436
GM-CSF 0.0001522 Sig. 0.0001522 Sig. 0.0001522 Sig.
CXCL1 0.4208 0.4502 0.4693
CXCL2 0.01102 0.4009 0.2884
CCL1 0.906 7.22E-07 Sig. 2.89E-07 Sig.
IFN-γ 1 0.6306 0.283
IL-1β 0.5762 0.7439 0.7263
IL-2 0.03306 0.07848 0.04296
IL-4 0.02215 8.60E-07 Sig. 1.75E-06 Sig.
IL-6 0.8887 0.8887 0.8887
IL-8 /CXCL8 0.01431 0.01431 0.01431
IL-10 0.0006389 Sig. 4.12E-05 Sig. 4.12E-05 Sig.
IL-16 0.06857 0.08816 0.08396
CXCL10 0.7032 0.7032 0.7032
CXCL11 0.8554 0.3009 0.2866
CCL2 0.6242 0.6242 0.6242
CCL8 0.6575 0.6575 0.6575
CCL7 0.4682 0.2802 0.1551
CCL13 0.0192 0.0192 0.0192
CCL22 0.07357 0.08864 0.1241
MIF 3.82E-07 Sig. 3.82E-07 Sig. 3.82E-07 Sig.
MIG/
CXCL9 0.5441 0.7089 0.7147
CCL3 0.01683 0.06466 0.0625
CCL15 0.4601 0.4601 0.4601
CCL20 0.5702 0.5702 0.5702
CCL19 0.2327 0.0002582 Sig. 0.0002039 Sig.
CCL23 0.4861 0.395 0.4041
CXCL16 0.05098 0.05098 0.05098
CXCL12 0.9804 0.6688 0.6689
CCL17 0.2207 0.1537 0.08507
CCL25 9.16E-05 Sig. 9.16E-05 Sig. 9.16E-05 Sig.
TNF-α 0.09276 0.09276 0.09276
TGF-β1 0.03058 0.00625 0.006766
TGF-β2 0.2662 0.2662 0.2662
TGF-β3 0.3009 0.001882 0.00419
No. of significant results
with NO correction
14 14 14
WITH Holm correction 5 8 8
LLOQ: Lower limit of quantitation. LOD: Lower of detection. Significant p-values are marked in bold.
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(0.1×, 0.5×, and 1.0×) of values below the LLOQ and
the LOD did not impact this outcome.
Discussion
Pro- and anti-inflammatory cytokines are partly
upregulated in the AH of patients with ERM, which
is in line with our previous findings of 2016 regard-
ing the vitreous,7 although findings from AH cannot
be expected to correlate with those from the vitreous
fluid.19
Of the cytokines that showed a significant differ-
ence between the two pathologic groups, CCL11, GM-
CFS, MIF, CCL25, CCL1, and CCL19 belong to the
proinflammatory cytokines, partially with chemoat-
tractant properties. Of these, CCL11 and CCL19
where upregulated for patients with ERM. The two
anti-inflammatory cytokines, IL-10 and IL-4, were
higher for patients with ERM compared with MH. As
mentioned in our article from 2016,7 because the levels
of given cytokines that are necessary for intercellular
communication and for the driving of relevant changes
in this milieu are still not well-known, we are unable to
assess the biological relevance of the measured differ-
ences between the two pathologic groups.
In our study, the concentration of several cytokines
was below the standard curve. However, these data
still may provide important information, namely, that
the concentrations of these cytokines are low in the
corresponding samples, which is relevant for the inter-
pretation of the mean. The exclusion of these results
from the calculations necessarily results in an upwards
shift of averages. Therefore, missing values can lead
to misinterpretation of statistical outcomes which can
be overcome by their substitution with the LOD or a
fraction (0.1–1.0 times) of the predefined LLOQ.
However, it remains to be determined whether or
when a statistical comparison in this situation is still
meaningful. We postulate, but cannot provide firm
evidence, that if more than 50% of data are below the
LLOQ, then the corresponding biomarker, in our series
cytokine, does not likely play a relevant role for the
bioregulation of the assessed environment. Because a
downregulation of the corresponding biomarker may
have taken place, we think that completely ignoring
biomarkers based on a high number of OOR data is
more dangerous than replacing them by 0.1- to 1.0-fold
the LLOQ or the LOD.
To corroborate the raw data, it may thus be advis-
able first to replace the missing values for results below
the LLOQ by a multiplicity of 0.1 to 1.0 of the LLOQ
or the LOD before applying a correction for multiple
comparison. Using this strategy reduced the number
of comparisons achieving significance from 33% (14
of 43) using the default setting of not weighing OOR
values and using a significance level to a P value of less
than 0.05 as in the automated statistical software, to
19% (8 of 43) in our model.
Assessing a single cytokine may reveal statistical
significance, but it is difficult to interpret its relevance
in a biological process where the pathophysiology of a
disease is not fully understood. The ease of compar-
ing multiple analytes in a single set of samples, in
contrast, may produce a lot of complex and interre-
lated data regarding the cytokine environment and its
changes in pathologic states, which harbors an inher-
ent risk of misinterpretation. The analysis of a single
or few cytokines may be of interest to analyze specific
biological processes, like specific immune responses.
The evaluation of multiple cytokines in parallel, in
contrast, may provide important insights into the local
cytokine environment in unknown or less specifically
regulated processes.
Data Below the Detection Limit (OOR<)
Handling OOR data as missing values may formally
be correct, but will not describe the biological regula-
tion in an environment such as the eye, which is known
to have biomarker concentrations at the lower end, at
least in healthy states. Therefore, minute changes to this
equilibrium may very well be meaningful. Excluding
these data would prevent detecting a possible downreg-
ulation of distinct markers and thus may lead to a
relevant bias and a potential underestimation of group
differences (Table 3). As mentioned, which fraction of
the LLOQ or the LOD were substituted had minimal
influence on the results. Substitution of the OOR data
with the LOD or different proportions of the LLOQ
(0.1, 0.5, and 1.0 of the LLOQ) revealed a difference
in means between MH and ERF for eight cytokines,
whereas no handling of the OORdata revealed a differ-
ence in only five cytokines, which would have failed
to identify significance for 3 of 43 cytokines (7%).
The consequent underestimation of group differences
increases the risk for a type II error.
Correcting for Multiple Comparisons
If large numbers of independent statistical tests
are performed on the same sample, the probability of
obtaining significant results will increase. That is, some
P values will be less than 0.05 just by chance. This
phenomenon results from choosing a significance level
of 0.05 which, by definition, results on average in 1
out of 20 comparisons being declared significant by
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chance alone, even if there is in fact no real difference
between the groups. In other words, performing multi-
ple comparisons increases the risk of a type I error.
The necessity to correct for multiple comparisons has
generally been accepted in the scientific community and
can be done by different methods like the Bonferroni
correction.17 Less conservative methods are Holm’s
correction,18 Hochberg (1988),20 Hommel (1988),21
Benjamini and Hochberg (1995),22 and Benjamini and
Yekutieli (2001).23 The first four methods control for
the family-wise error rate (Family-wise error rate is the
probability of one or more false rejections. The term
“family” refers to the collection of hypotheses H1,…..
Hs, which are being considered for joint testing17. Type
I errors can be defined as family-wise error rates23).
Hochberg’s and Hommel’s methods are best imple-
mented when the hypothesis tests are independent or
when they are non-negatively associated.21 Hommel’s
method is more robust to decrease a type I error than
Hochberg’s, but the difference is usually small and the
Hochberg P values are easier to compute. The methods
of Benjamini, Hochberg, andYekutieli control the false
discovery rate,22,23,26 that is, the expected proportion
of false positives among the rejected hypotheses. The
false discovery rate is a less stringent condition than
the family-wise error rate, so these methods are more
powerful than the others.17
The Bonferroni adjustment or correction is one
of the most often used methods; it is the easiest to
compute and uses a statistical significance level based
on the level for a single hypothesis divided by the
number of hypotheses tested. Thus, instead of setting
the level of significance at 0.05, the P value for signif-
icance is divided by the number of tests performed.
In our case, we tested the difference in 43 cytokines
between two groups: this led to aP level for significance
of 0.05/43 = 0.0012 (i.e., only results with a P value of
less than 0.0012 are accepted as significant). However,
this correction is a very conservative solution, which
in turns leads to a higher risk for type II errors.14
The Holm correction offers a good solution17,18 for
controlling type I errors, but at the same time without
drastically driving up type II errors, and is still easy
to compute. Holm’s correction, also called the sequen-
tially rejective Bonferroni test, progressively adapts the
threshold for rejecting the null hypotheses.
For our data, we chose to apply the Holm correc-
tion because it is not as restrictive as the Bonferroni
correction, but still simple enough that it can be easily
applied. The application of a correction for multiple
comparisons reduced the number of statistically signif-
icant differences by 50%: instead of 14 cytokines with a
significant difference between the two groups, we found
5 (P = 0.019) or 8 (P = 0.14), depending on whether
we substituted the OOR data or not. Much time and
effort for future research could be saved by not pursu-
ing nonexisting differences.
In conclusion, we were able to demonstrate a
relevant impact of handling OOR data to describe a
biological environment, and the importance of correc-
tion formultiple comparisons of samples with expected
low concentrations to understand their potential role
in a biological process. We strongly believe that any
biological process involves multiple interactions of
cytokines. Understanding and interpreting a patho-
physiologic process might thus be based on a broad
(multiplex) analysis of the local cytokine environment
instead of single cytokines, but has to providemeasures
to escape the inherent risks of multiple comparisons.
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